Concise Prescribing Info
Symptomatic treatment of OA (arthrosis, degenerative joint disease), RA & ankylosing spondylitis.
Dosage/Direction for Use
OA 7.5 mg daily, may be increased to 15 mg daily. RA 15 mg daily, may be reduced to 7.5 mg daily. Ankylosing spondylitis 15 mg daily. Patient w/ increased risks of AR Initially 7.5 mg daily. Long-term treatment of RA in elderly 7.5 mg daily. Dialysis patient w/ severe renal failure Not to exceed 7.5 mg daily. Total daily dosage: Not to exceed 15 mg.
May be taken with or without food: May be taken w/ meals if GI discomfort occurs.
Hypersensitivity to aspirin & other NSAIDs. Not to be given in patients who develop signs of asthma, nasal polyps, angioneurotic oedema or urticaria. Severe heart failure. Active or history of recurrent peptic ulcer/haemorrhage; history of GI bleeding or perforation related to previous NSAIDs therapy; cerebrovascular bleeding or other bleeding disorders. Severe hepatic failure. Non-dialyzed severe renal failure. Pregnancy & lactation. Childn <15 yr.
Special Precautions
Risk of GI ulceration, bleeding & perforation. Increased risk of serious CV events eg, MI; HTN; fluid retention or heart failure; history of serious GI events; smoking, alcoholism. Severe skin reactions eg, exfoliative dermatitis, toxic epidermal necrolysis or Stevens-Johnson syndrome. Concomitant use w/ corticosteroids. Avoid use during pregnancy. Not to be used during lactation. Not recommended in childn <15 yr. Elderly or debilitated patients.
Adverse Reactions
Anemia, blood count disturbances, leucocytopenia, thrombocytopenia; lightheadedness, headache; dyspepsia, nausea, vomiting, abdominal pain, constipation, flatulence, diarrhea, oesophagitis, stomatitis; pruritus, rash; edema.
Drug Interactions
Increased risk of ulcers & GI bleeding w/ other NSAIDs (eg, high-dose salicylates), corticosteroids. Increased risk of GI bleeding w/ antiplatelet agents, SSRIs. Enhanced effect of anticoagulants eg, warfarin. Increased risk of bleeding w/ oral anticoagulants, heparin, ticlopidine. Increased blood lithium levels. Accentuated haematologic toxicity of methotrexate. Decreased efficacy of IUD. Risk of acute renal failure in dehydrated patients w/ diuretics. Enhanced nephrotoxicity of cyclosporin. Decreased antihypertensive effect of β-blockers, ACE inhibitors, diuretics. Increased risk of haemorrhage w/ thrombolytics. Accelerated elimination by cholestyramine.
MIMS Class
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
ATC Classification
M01AC06 - meloxicam ; Belongs to the class of non-steroidal antiinflammatory and antirheumatic products, oxicams.
Avegesic tab 15 mg
5 × 10's
Avegesic tab 7.5 mg
5 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in